Related Experiment Video
Updated: Jun 15, 2026
The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Renal cell carcinoma and proteomics
Vanessa Sandim1, Denise A Pereira, Antonio A Ornellas
1Laboratório de Genética Aplicada, Serviço de Hematologia, Instituto Nacional do Câncer, Rio de Janeiro, Brasil. vsiqueira@inca.gov.br
Abstract:
Renal cell carcinoma (RCC) represents 3% of adult malignancies. About 30% of RCC patients develop metastatic disease. So far, drugs cannot significantly increase the survival of these patients. We present a recent review of proteomics and RCC. Proteomic technologies have been used in the research to discover new markers of RCC that might increase survival. Furthermore, newly discovered markers cannot increase patient survival, rather their prognostic value supporting therapeutic decisions or new agents targeted at these new markers. More research is required to develop proteomic technologies and biomarkers for identification and validation.
Insights
Proteomics research in renal cell carcinoma (RCC) aims to find new markers for better patient survival. However, current markers primarily aid in treatment decisions rather than directly improving outcomes for metastatic RCC patients.
Area of Science:
- Oncology
- Proteomics
- Biomarker Discovery
Background:
- Renal cell carcinoma (RCC) accounts for 3% of adult cancers.
- Metastatic disease develops in approximately 30% of RCC patients.
- Current treatments offer limited survival benefits for advanced RCC.
Purpose of the Study:
- To review the role of proteomics in renal cell carcinoma (RCC) research.
- To identify potential new biomarkers for RCC.
- To assess the clinical utility of identified biomarkers.
Main Methods:
- Review of recent literature on proteomics and RCC.
- Analysis of proteomic technologies for biomarker discovery.
- Evaluation of the prognostic and therapeutic implications of identified markers.
Main Results:
- Proteomic technologies have identified novel markers for RCC.
- Current biomarkers show prognostic value supporting therapeutic decisions.
- Newly discovered markers have not yet significantly increased patient survival.
Conclusions:
- Proteomics offers promise for advancing RCC research.
- Further development and validation of proteomic technologies and biomarkers are essential.
- Enhanced biomarker identification and validation are crucial for improving outcomes in metastatic RCC.
